MxA as a clinically applicable biomarker for identifying systemic interferon type i in primary Sjögren's syndrome

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 1052-1059

  Maria, Naomi I ^a   Brkic, Zana ^a   Waris, Matti ^b   Van Helden Meeuwsen, Cornelia G ^a   Heezen, Kim ^a   Van De Merwe, Joop P ^a   Van De Merwe, Paul L ^a   Dalm, Virgil A S H ^a   Drexhage, Hemmo A ^a   Versnel, Marjan A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; CD14 ANTIGEN; CD64 ANTIGEN; CORTICOSTEROID; HYDROXYCHLOROQUINE; INTERFERON; MYXOVIRUS RESISTANCE PROTEIN A; PILOCARPINE; SIALOADHESIN;

ADULT; AGED; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD ANALYSIS; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; COHORT ANALYSIS; ENZYME IMMUNOASSAY; EULAR SJOGREN SYNDROME DISEASE ACTIVITY INDEX; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IFI44 GENE; IFI44L GENE; IFIT3 GENE; LY6E GENE; MALE; MONOCYTE; MX1 GENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SJOEGREN SYNDROME; VERY ELDERLY;

DISEASE ACTIVITY; SJØGREN'S SYNDROME; TREATMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS; ANTIGENS, SURFACE; BIOLOGICAL MARKERS; COHORT STUDIES; CYTOSKELETAL PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GPI-LINKED PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON TYPE I; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MYXOVIRUS RESISTANCE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SJOGREN'S SYNDROME;

EID: 84899902260     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202552     Document Type: Article

References (41)

1. Skopouli FN, Dafni U, Ioannidis JP, et al. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum 2000;29: 296-304. (Pubitemid 30235981)
2. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61: 554-8. (Pubitemid 34539104)
3. Baccala R, Kono DH, Theofilopoulos AN. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 2005;204: 9-26. (Pubitemid 40460490)
4. Bave U, Nordmark G, Lovgren T, et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52: 1185-95. (Pubitemid 40530126)
5. Theofilopoulos AN, Baccala R, Beutler B, et al. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005;23: 307-36. (Pubitemid 40563172)
6. Nordmark G, Alm GV, Ronnblom L. Mechanisms of disease: primary Sjogren's syndrome and the type I interferon system. Nat Clin Pract Rheumatol 2006;2: 262-9.
7. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, et al. Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 2008;38: 2024-33.
8. Jonsson R, Vogelsang P, Volchenkov R, et al. The complexity of Sjogren's syndrome: novel aspects on pathogenesis. Immunol Lett 2011;141: 1-9.
9. Low HZ, Witte T. Aspects of innate immunity in Sjogren's syndrome. Arthritis Res Ther 2011;13:218.
10. Kimoto O, Sawada J, Shimoyama K, et al. Activation of the interferon pathway in peripheral blood of patients with Sjogren's syndrome. J Rheumatol 2011;38: 310-16.
11. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci U S A 2006;103: 2770-5.
12. Emamian ES, Leon JM, Lessard CJ, et al. Peripheral blood gene expression profiling in Sjogren's syndrome. Genes Immun 2009;10: 285-96.
13. Brkic Z, Maria NI, van Helden-Meeuwsen CG, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2013;72: 728-35.
14. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6: 975-90. (Pubitemid 350201788)
15. Airo P, Ghidini C, Zanotti C, et al. Upregulation of myxovirus-resistance protein A: a possible marker of type I interferon induction in systemic sclerosis. J Rheumatol 2008;35: 2192-200.
16. Biesen R, Demir C, Barkhudarova F, et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 2008;58: 1136-45. (Pubitemid 351564017)
17. York MR, Nagai T, Mangini AJ, et al. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 2007;56: 1010-20. (Pubitemid 46399451)
18. Lavie F, Miceli-Richard C, Ittah M, et al. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren's syndrome. Scand J Immunol 2008;67: 185-92.
19. Vallittu AM, Eralinna JP, Ilonen J, et al. MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients. Acta Neurol Scand 2008;118: 12-17. (Pubitemid 351809324)
20. Ittah M, Miceli-Richard C, Gottenberg JE, et al. B-cell-activating factor expressions in salivary epithelial cells after dsRNA virus infection depends on RNA-activated protein kinase activation. Eur J Immunol 2009;39: 1271-9.
21. Li Y, Lee PY, Kellner ES, et al. Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus. Arthritis Res Ther 2010;12:R90.
22. Hussein OA, El-Toukhy MA, El-Rahman HS. Neutrophil CD64 expression in inflammatory autoimmune diseases: its value in distinguishing infection from disease flare. Immunol Invest 2010;39: 699-712.
23. Tanaka M, Krutzik SR, Sieling PA, et al. Activation of Fc gamma RI on monocytes triggers differentiation into immature dendritic cells that induce autoreactive T cell responses. J Immunol 2009;183: 2349-55.
24. Crow MK. Interferon-alpha: a therapeutic target in systemic lupus erythematosus. Rheum Dis Clin North Am 2010;36:173-86, x.
25. Gao S, von der Malsburg A, Dick A, et al. Structure of myxovirus resistance protein a reveals intra- and intermolecular domain interactions required for the antiviral function. Immunity 2011;35: 514-25.
26. Ronni T, Melen K, Malygin A, et al. Control of IFN-inducible MxA gene expression in human cells. J Immunol 1993;150: 1715-26. (Pubitemid 23129647)
27. Haller O, Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 2011;31: 79-87.
28. Kracke A, von Wussow P, Al-Masri AN, et al. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology 2000;54: 193-9. (Pubitemid 30038759)
29. Muller-Doblies D, Ackermann M, Metzler A. In vitro and in vivo detection of Mx gene products in bovine cells following stimulation with alpha/beta interferon and viruses. Clin Diagn Lab Immunol 2002;9: 1192-9. (Pubitemid 35283279)
30. Kirou KA, Kalliolias GD. A new tool for detection of type I interferon activation in systemic lupus erythematosus. Arthritis Res Ther 2010;12:138.
31. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010;69: 1103-9.
32. Drexhage RC, van der Heul-Nieuwenhuijsen L, Padmos RC, et al. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J Neuropsychopharmacol 2010;13: 1369-81.
33. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia 2003;17: 2474-86. (Pubitemid 38072587)
34. Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-alphainduced genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3958-67. (Pubitemid 39643944)
35. Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54: 2951-62. (Pubitemid 44497776)
36. Boros P, Muryoi T, Spiera H, et al. Autoantibodies directed against different classes of Fc gamma R are found in sera of autoimmune patients. J Immunol 1993;150: 2018-24. (Pubitemid 23129680)
37. Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005;1050: 34-9. (Pubitemid 41129420)
38. Yoshimoto K, Tanaka M, Kojima M, et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjogren's syndrome. Arthritis Res Ther 2011;13:R170.
39. Sacre K, Criswell LA, McCune JM. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 2012;14:R155.
40. Kariuki SN, Niewold TB. Genetic regulation of serum cytokines in systemic lupus erythematosus. Transl Res 2010;155: 109-17.
41. Nordmark G, Eloranta ML, Ronnblom L. Primary Sjogren's syndrome and the type I interferon system. Curr Pharm Biotechnol 2012;13: 2054-62.